Search

Your search keyword '"Suri, Anuj"' showing total 23 results
Start Over Author "Suri, Anuj"
23 results on '"Suri, Anuj"'

22. The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer

Author

Zhou, Chunxiao, Bae-Jump, Victoria L., Schuler, Kevin M., Suri, Anuj, Zhong, Yan, Han, Xiaoyun, Gehrig, Paola A., Sheng, Xiugui, and Jones, Hannah M.

Subjects
2. Zero hunger, 3. Good health
Abstract

Our objective was to evaluate the effect of the COX-2 inhibitor, celecoxib, on (1) proliferation and apoptosis in human ovarian cancer cell lines and primary cultures of ovarian cancer cells, and (2) inhibition of tumor growth in a genetically engineered mouse model of serous ovarian cancer under obese and non-obese conditions. Celecoxib inhibited cell proliferation in three ovarian cancer cell lines and five primary cultures of human ovarian cancer after 72 hours of exposure. Treatment with celecoxib resulted in G1 cell cycle arrest, induction of apoptosis, inhibition of cellular adhesion and invasion and reduction of expression of hTERT mRNA and COX-2 protein in all of the ovarian cancer cell lines. In the KpB mice fed a high fat diet (obese) and treated with celecoxib, tumor weight decreased by 66% when compared with control animals. Among KpB mice fed a low fat diet (non-obese), tumor weight decreased by 46% after treatment with celecoxib. In the ovarian tumors from obese and non-obese KpB mice, treatment with celecoxib as compared to control resulted in decreased proliferation, increased apoptosis and reduced COX-2 and MMP9 protein expression, as assessed by immunohistochemistry. Celecoxib strongly decreased the serum level of VEGF and blood vessel density in the tumors from the KpB ovarian cancer mouse model under obese and non-obese conditions. This work suggests that celecoxib may be a novel chemotherapeutic agent for ovarian cancer prevention and treatment and be potentially beneficial in both obese and non-obese women.

23. Evaluating Women With Ovarian Cancer for BRCA1and BRCA2Mutations Missed Opportunities

Author

Meyer, Larissa A., Anderson, Meaghan E., Lacour, Robin A., Suri, Anuj, Daniels, Molly S., Urbauer, Diana L., Nogueras-Gonzalez, Graciela M., Schmeler, Kathleen M., Gershenson, David M., and Lu, Karen H.

Abstract

Germline mutations in 2 genes, BRCA1and BRCA2, account for the majority of hereditary breast and ovarian cancer families. Clinical genetic tests are available to identify individuals with these mutations. Almost 50% of ovarian cancer patients who undergo such testing have been found to have a deleterious mutation in BRCA1or BRCA2. Published guidelines of the American College of Obstetricians and Gynecologists recommend that ovarian cancer patients at a substantial (more than 20%–25%) risk for having BRCA1or BRCA2mutations should be referred for genetic counseling. The investigators hypothesized that a significant number of ovarian cancer patients with a personal or family history highly suggestive for a BRCA1or BRCA2mutation were not being identified and referred for genetic counseling.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results